Rifampin inhibits prostaglandin E2 production and arachidonic acid release in human alveolar epithelial cells

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4225-4230

  Yuhas, Yael ^a   Azoulay Alfaguter, Inbar ^a   Berent, Eva ^a   Ashkenazi, Shai ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; RIFAMPICIN;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION;

ARACHIDONIC ACID; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INTERLEUKIN-1BETA; PHOSPHOLIPASES A2; PHOSPHORYLATION; PULMONARY ALVEOLI; RESPIRATORY MUCOSA; RIFAMPIN;

EID: 36749091713     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00985-07     Document Type: Article

References (31)

1. Aronoff, D. M., C. Canetti, and M. Peters-Golden. 2004. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173:559-565.
2. Bafica, A., C. A. Scanga, C. Serhan, F. Machado, S. White, A. Sher, and J. Aliberti. 2005. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Investig. 115:1601-1606.
3. Cabral, G. A. 2005. Lipids as bioeffectors in the immune system. Life Sci. 77:1699-1710.
4. Calleja, C., J. M. Pascussi, J. C. Mani, P. Maurel, and M. J. Vilarem. 1998. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 4:92-96.
5. D'Avila, H., R. C. Melo, G. G. Parreira, E. Werneck-Barroso, H. C. Castro-Faria-Neto, and P. T. Bozza. 2006. Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J. Immunol. 176:3087-3097.
6. Diaz, B. L., and J. P. Arm. 2003. Phospholipase A(2). Prostaglandins Leukot. Essent. Fatty Acids 69:87-97.
7. Duan, L., H. Gan, J. Arm, and H. G. Remold. 2001. Cytosolic phospholipase A2 participates with TNF-alpha in the induction of apoptosis of human macrophages infected with Mycobacterium tuberculosis H37Ra. J. Immunol. 166:7469-7476.
8. Freire-de-Lima, C. G., D. O. Nascimento, M. B. Soares, P. T. Bozza, H. C. Castro-Faria-Neto, F. G. de Mello, G. A. DosReis, and M. F. Lopes. 2000. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403:199-203.
9. Gil, D., L. F. Garcia, and M. Rojas. 2003. Modulation of macrophage apoptosis by antimycobacterial therapy: physiological role of apoptosis in the control of Mycobacterium tuberculosis. Toxicol. Appl. Pharmacol. 190:111- 119.
10. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23:144-150.
11. Herr, A. S., G. M. Wochnik, M. C. Rosenhagen, F. Holsboer, and T. Rein. 2000. Rifampicin is not an activator of glucocorticoid receptor. Mol. Pharmacol. 57:732-737.
12. Jaffuel, D., P. Demoly, C. Gougat, G. Mautino, J. Bousquet, and M. Mathieu. 1999. Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells. Mol. Pharmacol. 55:841-846.
13. Miller, S. B. 2006. Prostaglandins in health and disease: an overview. Semin. Arthritis Rheum. 36:37-49.
14. Mlambo, G., and L. B. Sigola. 2003. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int. Immunopharmacol. 3:513-522.
15. 2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci. 60:67-78.
16. Newton, R., L. Cambridge, L. A. Hart, D. A. Stevens, M. A. Lindsay, and P. J. Barnes. 2000. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br. J. Pharmacol. 130:1353-1361.
17. Pahlevan, A. A., D. J. Wright, L. Bradley, C. Smith, and B. M. Foxwell. 2002. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J. Antimicrob. Chemother. 49:531-534.
18. Rangel Moreno, J., I. Estrada García, M. De La Luz García Hernandez, D. Aguilar Leon, R. Marquez, and R. Hernández Pando. 2002. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106:257-266.
19. Roy, S., S. Sharma, M. Sharma, R. Aggarwal, and M. Bose. 2004. Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis. Immunology 112:471-480.
20. Sharma, M., S. Sharma, S. Roy, S. Varma, and M. Bose. 2007. Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. Immunol. Cell Biol. 85:229-237.
21. Tentori, L., G. Graziani, S. A. Porcelli, M. Sugita, M. B. Brenner, R. Madaio, E. Bonmassar, A. Giuliani, and A. Aquino. 1998. Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrob. Agents Chemother. 42:550-554.
22. Tilley, S. L., T. M. Coffman, and B. H. Koller. 2001. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Investig. 108:15-23.
23. Turnidge, J. D., and J. H. Jorgensen. 1999. Antimicrobial susceptibility testing: general consideration, p. 1469-1473. In P. R. Murray, E. J. Baron, M. A. Pfaller, et al. (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
24. Venkataprasad, N., H. Shiratsuchi, J. L. Johnson, and J. J. Ellner. 1996. Induction of prostaglandin E2 by human monocytes infected with Mycobacterium avium complex - modulation of cytokine expression. J. Infect. Dis. 174:806-811.
25. Wallach, D. 1984. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J. Immunol. 132:2464-2469.
26. Wen, H. C., and W. W. Lin. 2000. Basal cPLA(2) phosphorylation is sufficient for Ca(2+)-induced full activation of cPLA(2) in A549 epithelial cells. J. Cell. Biochem. 79:601-609.
27. Yerramasetti, R., S. Gollapudi, and S. Gupta. 2002. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J. Clin. Immunol. 22:37-47.
28. Yoshikai, Y. 2001. Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection. Curr. Opin. Infect. Dis. 14:257-263.
29. Yuan, S., P. L. Tan, and M. A. Skinner. 1994. The effect of prostaglandin E2 and indomethacin on the cytotoxic response to mycobacterial antigens. Int. J. Immunopharmacol. 16:525-531.
30. Yuhas, Y., E. Berent, H. Ovadiah, I. Azoulay, and S. Ashkenazi. 2006. Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells. Antimicrob. Agents Chemother. 50:396-398.
31. Ziglam, H. M., I. Daniels, and R. G. Finch. 2004. Immunomodulating activity of rifampicin. J. Chemother. 16:357-361.